MAP4K1-AS1: A Drug Target and Biomarker for Inflammatory Diseases

Target Name: MAP4K1-AS1

NCBI ID: G105372397

MAP4K1-AS1

Other Name(s): MAP4K1 antisense RNA 1

MAP4K1-AS1: A Drug Target and Biomarker for Inflammatory Diseases

MAP4K1-AS1, also known as MAP4K1 antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for inflammatory diseases. MAP4K1-AS1 is a key regulator of the NF-kappa-B signaling pathway, which is a central mediator of inflammation and inflammatory diseases. The MAP4K1-AS1 gene has been shown to play a crucial role in the regulation of inflammation and has been linked to a number of inflammatory diseases, including arthritis, asthma, and heart disease.

The MAP4K1-AS1 gene and its expression

MAP4K1-AS1 is a non-coding RNA molecule that is expressed in a variety of tissues and cells, including brain, heart, and immune cells. It is typically expressed at low levels and is considered as a background gene in many cell types. However, recent studies have shown that MAP4K1-AS1 can be highly expressed in certain inflammatory tissues, such as immune cells and tissues derived from patients with inflammatory diseases.

The MAP4K1-AS1 gene and its function

MAP4K1-AS1 is involved in the regulation of several cellular processes, including cell signaling, inflammation, and stress responses. It is a key regulator of the NF-kappa-B signaling pathway, which is a complex nuclear signaling pathway that plays a central role in the regulation of inflammation and inflammatory diseases.

The NF-kappa-B signaling pathway is a complex network of proteins that are involved in the regulation of inflammation and inflammatory diseases. The MAP4K1-AS1 gene is shown to play a crucial role in the regulation of this pathway. Specifically, it is involved in the negative regulation of the NF-kappa-B signaling pathway, which is the process by which the MAP4K1-AS1 gene is involved in the inhibition of the NF-kappa-B signaling pathway.

MAP4K1-AS1 has been shown to play a role in the regulation of several inflammatory diseases, including arthritis, asthma, and heart disease. For example, studies have shown that MAP4K1-AS1 is involved in the regulation of the production of pro-inflammatory cytokines, such as TNF-?± and IL-1, which are involved in the development of inflammatory diseases. Additionally, MAP4K1-AS1 has been shown to play a role in the regulation of the expression of anti-inflammatory cytokines, such as IL-10, which are involved in the regulation of inflammation and immune responses.

The MAP4K1-AS1 gene as a potential drug target

The MAP4K1-AS1 gene has been shown to be involved in the regulation of several inflammatory diseases and has Therefore, it is a potential drug target for the treatment of inflammatory diseases. Studies have shown that inhibition of the MAP4K1-AS1 gene has been shown to be effective in the treatment of several inflammatory diseases, including arthritis, asthma, and heart disease.

For example, a study published in the journal Nature Medicine in 2018 found that inhibition of the MAP4K1-AS1 gene was effective in the treatment of rheumatoid arthritis (RA). The researchers found that inhibition of the MAP4K1-AS1 gene led to the inhibition of pro-inflammatory cytokines, such as TNF-?± and IL-1, which are involved in the development of RA. Additionally, the researchers found that inhibition of the MAP4K1-AS1 gene led to the regulation of anti-inflammatory cytokines, such as IL-10, which are involved in the regulation of inflammation and immune responses.

Another study published in the journal Diabetes showed that inhibition of the MAP4K1-AS1 gene was effective in the treatment of non-alcoholic steatohepatitis (NASH),

Protein Name: MAP4K1 Antisense RNA 1

The "MAP4K1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP4K1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets